Comprehensive Cancer Center Tübingen-Stuttgart
Tübingen's cancer centre, the cradle of peptide cancer vaccines and the Immatics and CureVac spin-outs, with a strong melanoma and PET/MRI tradition.
The CCC Tübingen-Stuttgart is a German Cancer Aid Oncology Center of Excellence, DKTK partner site and, since 2023, part of the National Center for Tumor Diseases SouthWest. Hans-Georg Rammensee's immunology department mapped tumour-presented HLA peptides and spawned Immatics (TCR-based therapies) and, with Ingmar Hoerr, CureVac (mRNA), while the university's dermatology clinic is one of Europe's major melanoma centres. The Werner Siemens Imaging Center under Bernd Pichler pioneered combined PET/MRI, and the hospital runs large haematology, neuro-oncology and paediatric oncology programmes. Patients have access to peptide vaccine and TCR-T trials as well as molecular tumour boards.
- Tumour immunology and peptide vaccines
- Melanoma
- PET/MRI and preclinical imaging
- NCT SouthWest
- Paediatric oncology
Pages like this
not linked directly; found by shared links- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Off-the-shelf cancer vaccines, Neoantigen, TCR-T cell therapy, Acute myeloid leukaemia.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- InstitutionUniversity Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz
Shares German Cancer Research Center (DKFZ), Neoantigen, Personalised neoantigen (mRNA) vaccines, Melanoma.
- InstitutionLausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Shares Neoantigen, TCR-T cell therapy, Personalised neoantigen (mRNA) vaccines, Glioma & glioblastoma.
- IdeaVaccinate against the resistance mutation before it takes over
Shares Off-the-shelf cancer vaccines, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- ProductDCVax-L
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines, Glioma & glioblastoma.
- IdeaAntibodies that see mutant KRAS and p53 fragments displayed on the cell surface
Shares Immatics, Neoantigen, TCR-T cell therapy.
- CompanySerova